CST3 and acute kidney injury: Over the last decade, there have been many promising biomarkers such as Cystatin-C, NGAL, KIM-1 that assess the acute renal dysfunction.8 The availability of these new markers offers an unprecedented opportunity for improved evaluation and management of patients with AKI.